Esperion Closes Corstasis Acquisition, Bolstering Cardiovascular Franchise with Enbumyst™
ESPR has more than doubled off its 52-week low of $0.693.
Summary
Esperion Therapeutics has completed its acquisition of Corstasis Therapeutics, a significant strategic move that expands its cardiovascular franchise. This transaction integrates Enbumyst (bumetanide nasal spray) into Esperion's product pipeline, enhancing its offerings in a key therapeutic area. While Esperion's recent 10-K on March 10, 2026, had confirmed the company's intent for a strategic acquisition, the official closing of the deal is a material development. This event is expected to bolster Esperion's long-term growth prospects and competitive position, with investors now watching for details on the integration process and commercialization plans for Enbumyst.
At the time of this announcement, ESPR was trading at $2.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $671.6M. The 52-week trading range was $0.69 to $4.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.